There’s a massive push to remove respiratory syncytial virus (RSV) vaccines from the market after data presented by the CDC’s Advisory Committee on Immunization Practices (ACIP) disclosed the figures on deaths and adverse events.

“CDC data and the Vaccine Adverse Event Reporting System (VAERS) already show reports of 34 deaths, 302 serious adverse events and according to news reports this week, a safety signal for Guillain-Barré syndrome (GBS),” The Defender reports.

Last year, the U.S. Food and Drug Administration (FDA) approved Pfizer’s Abrysvo and GSK’s Arexvy RSV vaccines for adults ages 60 and older.

“Abrysvo is also approved for pregnant women, targeting RSV prevention in babies. The FDA approved Abrysvo and Arexvy in May 2023,” The Defender noted.

Dr. Peter McCullough said the RSV shots “should be pulled off the market immediately.”

“16M shots. Among 34 deaths, a pregnant woman, multiple adults particularly when RSV is given with Influenza or COVID-19 vaccines,” he added.

The Defender reports:

Members of the CDC’s Advisory Committee on Immunization Practices (ACIP) presented the data on deaths and adverse events related to the RSV vaccines at a Feb. 29 meeting.

Yet, ACIP — and news media reports — primarily focused on GBS safety signals, glossing over deaths and the administration of the vaccines to unauthorized age groups.

Instead, CDC officials claimed it’s too early to determine if the RSV vaccines caused the adverse events and reiterated that the shots are safe, according to The Associated Press (AP).

Experts who spoke with The Defender disputed the CDC’s reassurances. Brian Hooker, Ph.D., chief scientific officer for Children’s Health Defense (CHD), said “34 deaths in 10 months should be sufficient to pull the RSV vaccines from the market. But the FDA will not do that — nor will there be full investigations regarding these deaths.”

“I am greatly concerned with the excessive application of the RSV vaccine,” said cardiologist Dr. Peter McCullough. “We are beginning to see the tip of the iceberg in terms of serious side effects.”

According to the CDC data presented at the Feb. 29 ACIP meeting, of the 34 deaths reported as of Feb. 16 following RSV vaccination, 22 were linked to Arexvy and nine to Abrysvo. In three instances, the report listed “no brand name.”

Instead of pulling the RSV shots off the market, officials will ‘investigate’ reports of Guillain-Barre syndrome.

“Serious neurologic conditions, including Guillain-Barre syndrome (GBS), have been reported after RSV vaccination in clinical trials of older adults. It is unclear whether the vaccine caused these events,” the CDC writes.

The Associated Press previously reported that officials are investigating more than 20 cases of Guillain-Barre syndrome.

From the Associated Press:

Officials said they were investigating more than 20 cases of Guillain-Barre syndrome, an rare illness in which a person’s immune system damages nerve cells, causing muscle weakness and paralysis. An estimated 3,000 to 6,000 people develop GBS in the U.S. each year, and it’s more commonly seen in older people, according to the CDC.

Most people fully recover from the syndrome, but some have permanent nerve damage. Guillain-Barre can occur in people after they are infected with a virus, but in some instances cases have been linked to vaccinations.

RSV, or respiratory syncytial virus, is a common cause of cold-like symptoms but it can be dangerous for infants and the elderly.

Last year, the CDC signed off on a recommendation made by the advisory panel, aimed at Americans age 60 and older. It was for a single dose of RSV vaccine. There were two options, one made by Pfizer and the other by GSK.

“VAERS lists 3,834 adverse events relating to the RSV vaccines as of Feb. 23, with approximately two-thirds of the reports pertaining to Arexvy. A total of 302 reports are classified as serious adverse events, with slightly over half connected to Arexvy,” The Defender writes.

More from The Defender:

Yet, the ACIP meeting and subsequent news stories largely focused on a single safety signal: a higher-than-normal incidence of GBS in RSV vaccine recipients.

According to The New York Times, GBS causes the immune system to attack the nerves, leading to paralysis and death in severe cases. According to AP, “An estimated 3,000 to 6,000 people develop G.B.S. in the U.S. each year,” mostly older adults.

“Rare cases of Guillain-Barré syndrome have been linked to other vaccines, including those against influenza and shingles,” the Times reported. The Times did not mention incidences of GBS connected to COVID-19 vaccination.

AP reported that health officials estimate “About two cases of Guillain-Barré might be seen in every 1 million people who receive a vaccine.” CDC data indicate the GBS incidence rate for Abrysvo recipients was 4.6 cases per million people.

 

Join The Conversation. Leave a Comment.


We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. If a comment is spam, instead of replying to it please click the ∨ icon below and to the right of that comment. Thank you for partnering with us to maintain fruitful conversation.